Clinical Trial

Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension

Study acronym: ATHESA
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase III, non-inferiority, randomized, double-blind, double-dummy, active-controlled, multicenter study to compare the efficacy and safety of N0877 versus double combination with already established efficacy on systolic blood pressure (SBP) in the sitting position in the medical office in patients with SAH after 8 weeks of treatment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-09-20; most recent amendment 2024-11-26.
Trial Details
NCT Number NCT06608472
Lead Sponsor Eurofarma Laboratorios S.A.
Conditions Essential Arterial Hypertension
Enrollment 292 participants
Start Date 2026-11-30
Primary Completion 2028-04-30 (estimated)
Study Completion 2029-10-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-27